ALK and non-small cell lung carcinoma: Therefore, the implication of our study is not that lorlatinib should be withheld from patients with untreated ALK+ NSCLC; in particular, the advantages of lorlatinib treatment over crizotinib include slower progression of brain metastases for patients receiving long-term treatment (54).